康方生物:本公司与中国生物制药有限公司共同开发的PD-1单抗药物派安普利单抗(安尼可)在至少进行了2次疗效评估的r/r cHL受试者中表现出显著的临床获益

云财经
Nov 12, 2020

云财经讯,康方生物:本公司与中国生物制药有限公司共同开发的PD-1单抗药物派安普利单抗(安尼可)在至少进行了2次疗效评估的r/r cHL受试者中表现出显著的临床获益。其中,客观缓解率(ORR)达到83.6%,完全缓解率(CR)达到 49.3%,明显高于历史对照,且优于目前有条件获批上市的PD-1单抗已公布数据

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10